In addition, cis‐MR analyses have used the HMGCR region as a benchmark to assess the suitability of other genetic regions as potential drug targets for CHD risk; this includes the PCSK9 (Ference et al., 2016) and ACLY (Ference et al., 2019) regions. This evidence concerns the gene HMGCR and coronary artery disorder.